Combining chemotherapy with a new treatment method for pancreatic cancer
Official title: A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
Funded at University of Texas Hlth Sci Ctr Houston · NIH-10846817 · Data updated 2026-11-12
This study is looking at how well combining regular chemotherapy with a special treatment called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) works for people with pancreatic cancer, hoping to boost their immune response and improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $621,551 |
| NIH project number | 5R01CA277161-02 |
| Project ID | NIH-10846817 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with resectable pancreatic ductal adenocarcinoma who are eligible for chemotherapy.
✕Less likely to help
Patients with advanced or metastatic pancreatic cancer may not benefit from this research as it focuses on those with resectable tumors.
What this research studies
This research investigates the safety and effectiveness of combining standard chemotherapy with endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for patients with pancreatic ductal adenocarcinoma (PDAC). The approach aims to address the challenges posed by the tumor's resistant nature and its complex microenvironment. By using EUS-RFA, the study seeks to improve the immune response against the cancer and potentially enhance the overall treatment outcomes. Patients will be closely monitored to assess the impact of this combined therapy on tumor progression and survival rates.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better treatment options for patients with pancreatic cancer.
How similar studies have gone: Previous studies have shown promising results with similar approaches, indicating potential for significant advancements in treating pancreatic cancer.
Where this research is happening
-
University of Texas Hlth Sci Ctr Houston
Houston, United States Active
Researchers
- Principal investigator: Thosani, Nirav — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Thosani, Nirav
Related research
Other NIH-funded projects on the same topics.
-
A targeted therapy plan using endoscopic heat treatment plus chemotherapy for pancreatic cancer
A patient-focused plan tests using a special endoscopic heat treatment together with chemotherapy to treat pancreatic cancer.
-
Combining Chemotherapy with Targeted Ablation for Pancreatic Cancer
This research is testing a new way to treat pancreatic cancer by combining standard chemotherapy with a targeted heat treatment called radiofrequency ablation.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
3D ultrasound method to see early breast cancer response to chemotherapy
A new 3D ultrasound imaging method is being tested to quickly tell if breast cancer is responding to chemotherapy, using a FDA-cleared scanner at an affordable cost.
-
3D ultrasound to detect early breast tumor response to chemotherapy
A 3D quantitative ultrasound scanner will be used to detect early changes in breast tumors during chemotherapy for people with breast cancer.
-
Combination therapy with a T-cell engager and chemotherapy for pancreatic cancer
A new treatment approach combines a T-cell engaging antibody with standard chemotherapy to help treat pancreatic cancer, aiming to slow tumor growth and improve outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.